Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05553301 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older
A Phase 1 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 560
- Enrollment target
NCT05553301 is a Phase 1 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 560 participants.
The verdict
NCT05553301, a Phase 1 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 560 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 2 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5407 compared to an active control (QIV standard-dose (SD), QIV high-dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.
Interventions
- BIOLOGICAL Quadrivalent Influenza Standard Dose Vaccine
- BIOLOGICAL Quadrivalent Recombinant Influenza Vaccine
- BIOLOGICAL Quadrivalent Influenza mRNA Vaccine MRT5407
- BIOLOGICAL Quadrivalent Influenza High-Dose Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2024-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05553301
The ClinicalTrials.gov registry entry for NCT05553301 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 560 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Quadrivalent Influenza Standard Dose Vaccine is the first listed.
NCT05553301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05553301 about?
NCT05553301 is a clinical study titled "Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older". The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 2 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5407 compared to an active control (QIV standard-dose (SD), QIV high-dose (HD) \[adults ≥ 65 y...
What is the current status of trial NCT05553301?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 560 participants. The study started on 2022-10-03. Estimated completion is 2024-01-19.
What interventions are being tested in trial NCT05553301?
The interventions under investigation include: Quadrivalent Influenza Standard Dose Vaccine (BIOLOGICAL), Quadrivalent Recombinant Influenza Vaccine (BIOLOGICAL), Quadrivalent Influenza mRNA Vaccine MRT5407 (BIOLOGICAL), Quadrivalent Influenza High-Dose Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05553301?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.